Clinical Trials Directory

Trials / Completed

CompletedNCT06822335

Clinical Efficacy of the Product in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP) Subjects

Evaluation of the Efficacy of Niacinamide a in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP) Test Under Dermatological Control

Status
Completed
Phase
Study type
Observational
Enrollment
65 (actual)
Sponsor
Cosmetique Active International · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

Double-blind, randomized, clinical study is designed to evaluate the efficacy of Niacinamide A in the management of facial Post Inflammatory Hyper Pigmentation (PIHP) in healthy female and male subjects with moderate to severe PIHP due to acne, mild acne and (≤4) inflammatory lesions, its impact on skin lightening effect and lastly any associated benefits on skin quality.

Detailed description

Primary objective To investigate the depigmenting effect of Niacinamide A in moderate to severe facial post inflammatory hyperpigmentation due to acne after a 12-week application period. Secondary objectives To evaluate any associated benefit of the product on skin condition and skin imperfection at different timepoints: Product lightening efficacy using the Spectrocolorimeter. Evaluation of the global assessment evaluation for acne severity by the investigator using a 6 -point scale. Counting of non-inflammatory and inflammatory lesions to access the change on the face. Investigator scoring to assess the local intolerance (erythema, edema, dryness). Subject scoring to assess the local intolerance(burning, stinging, itching and tingling sensations). Subjective assessment of global tolerance of the product using a 4-point scale. Skin imaging analysis to assess the evaluation of the PIHP(darkness, size, number brown spots). Evaluation of the mean darkness. Subjective evaluation of Global Assessment(SGA). Subject questionnaires to assess consumer perceived skin endpoints by filling in a cosmetic evaluation questionnaire and a stigmatization questionnaire.

Conditions

Timeline

Start date
2023-04-03
Primary completion
2023-08-07
Completion
2023-08-08
First posted
2025-02-12
Last updated
2025-02-12

Locations

1 site across 1 country: Mauritius

Source: ClinicalTrials.gov record NCT06822335. Inclusion in this directory is not an endorsement.